Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

  • Andy C Rawstron, Danmark
  • Alberto Orfao, Danmark
  • Meral Beksac, Danmark
  • Ludmila Bezdickova, Danmark
  • Rik A Brooimans, Danmark
  • Horia Bumbea, Danmark
  • Klara Dalva, Danmark
  • Gwenny Fuhler, Danmark
  • Jan Gratama, Danmark
  • Dirk Hose, Danmark
  • Lucie Kovarova, Danmark
  • Michael Lioznov, Danmark
  • Gema Mateo, Danmark
  • Ricardo Morilla, Danmark
  • Anne K Mylin, Danmark
  • Paola Omedé, Danmark
  • Catherine Pellat-Deceunynck, Danmark
  • Martin Perez Andres, Danmark
  • Maria Petrucci, Danmark
  • Marina Ruggeri, Danmark
  • Grzegorz Rymkiewicz, Danmark
  • Alexander Schmitz, Danmark
  • Martin Schreder, Danmark
  • Carine Seynaeve, Danmark
  • Martin Spacek, Danmark
  • Ruth M de Tute, Danmark
  • Els Van Valckenborgh, Danmark
  • Nicky Weston-Bell, Danmark
  • Roger G Owen, Danmark
  • Jesús F San Miguel, Danmark
  • Pieter Sonneveld, Danmark
  • Hans E Johnsen, Danmark
  • European Myeloma Network
  • Hæmatologisk Forskningsenhed, Aalborg Sygehus
  • Molekylærbiologisk Institut
The European Myeloma Network (EMN) organized two flow cytometry workshops. The first aimed to identify specific indications for flow cytometry in patients with monoclonal gammopathies, and consensus technical approaches through a questionnaire-based review of current practice in participating laboratories. The second aimed to resolve outstanding technical issues and develop a consensus approach to analysis of plasma cells. The primary clinical applications identified were: differential diagnosis of neoplastic plasma cell disorders from reactive plasmacytosis; identifying risk of progression in patients with MGUS and detecting minimal residual disease. A range of technical recommendations were identified, including: 1) CD38, CD138 and CD45 should all be included in at least one tube for plasma cell identification and enumeration. The primary gate should be based on CD38 vs. CD138 expression; 2) after treatment, clonality assessment is only likely to be informative when combined with immunophenotype to detect abnormal cells. Flow cytometry is suitable for demonstrating a stringent complete remission; 3) for detection of abnormal plasma cells, a minimal panel should include CD19 and CD56. A preferred panel would also include CD20, CD117, CD28 and CD27; 4) discrepancies between the percentage of plasma cells detected by flow cytometry and morphology are primarily related to sample quality and it is, therefore, important to determine that marrow elements are present in follow-up samples, particularly normal plasma cells in MRD negative cases.
Udgivelsesdato: 2008-Mar
OriginalsprogEngelsk
TidsskriftHaematologica
Vol/bind93
Nummer3
Sider (fra-til)431-8
Antal sider7
ISSN0390-6078
DOI
StatusUdgivet - 2008

Se relationer på Aarhus Universitet Citationsformater

ID: 10919873